Work

Phase 1 trial of a KRAS G12V/HLA-A*11:01–restricted TCR-engineered T-cell therapy in advanced solid tumors.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2542

Authors: Ding Xiaoyan, Wen Zhang, Ying Teng, Chun-Xia Du, Wenying Qiao, Ronghua Jin, Jinglong Chen, Zhen Huang, Zhichao Jiang, Lin Yang, Yefan Zhang, Dongbing Zhao, Hai-Tao Zhou, Yihebali Chi, Shun He, Jianming Ying, Yongkun Sun, Chaoying Hu, Hong Zhao

Institutions: Capital Medical University, Beijing Ditan Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, State Key Laboratory of Molecular Oncology

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162525251

Cites:

Cited by: 1

Related to: